Efficacy and tolerability of add‐on stiripentol in real‐world clinical practice: An observational study in Dravet syndrome and non‐Dravet developmental and epileptic encephalopathies
Open Access
- 8 November 2023
- journal article
- research article
- Published by Wiley in Epilepsia Open
- Vol. 9 (1) , 164-175
Abstract
Objective: To assess efficacy and tolerability of stiripentol (STP) as adjunctive treatment in Dravet syndrome and non‐Dravet refractory developmental and epileptic encephalopathies (DREEs).Methods: Retrospective observational study of all children and adults with DREE and prescribed adjunctive STP at Hospital Ruber Internacional from January 2000 to February 2023. Outcomes were retention rate, responder rate (proportion of patients with ≥50% reduction in total seizure frequency relative to baseline), seizure freedom rate, responder rate for status epilepticus, rate of adverse event and individual adverse events, reported at 3, 6, and 12 months and at final visit. Seizure outcomes are reported overall, and for Dravet and non‐Dravet subgroups.Results: A total of 82 patients (55 Dravet syndrome and 27 non‐Dravet DREE) were included. Median age was 5 years (range 1–59 years), and median age of epilepsy onset was younger in the Dravet group (4.9 [3.6–6] months) than non‐Dravet (17.9 [6–42.3], P < 0.001). Median follow‐up time STP was 24.1 months (2 years; range 0.3–164 months) and was longer in the Dravet group (35.9 months; range 0.8–164) than non‐Dravet (17 months range 0.3–62.3, P < 0.001). At 12 months, retention rate, responder rate and seizure free rate was 68.3% (56/82), 65% [48–77%] and 18% [5.7–29%], respectively. There were no statistically significant differences between groups on these seizure outcomes. Adverse events were reported in 46.3% of patients (38/82), without differences between groups.Significance: In this population of patients with epileptic and developmental encephalopathies, outcomes with adjunctive STP were similar in patients with non‐Dravet DREE to patients with Dravet syndrome.Keywords
This publication has 34 references indexed in Scilit:
- Neuroprotective activity of stiripentol with a possible involvement of voltage‐dependent calcium and sodium channelsJournal of Neuroscience Research, 2015
- Targeting LDH enzymes with a stiripentol analog to treat epilepsyScience, 2015
- Polytherapy with stiripentol: Consider more than just metabolic interactionsEpilepsy & Behavior, 2013
- Stiripentol in refractory status epilepticusEpilepsia, 2013
- Malignant migrating partial seizures of infancy controlled by stiripentol and clonazepamBrain and Development, 2013
- The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocolBrain, 2011
- Retention rate of Clobazam, Topiramate and Lamotrigine in children with intractable epilepsies at 1 yearSeizure: European Journal of Epilepsy, 2011
- The anti-convulsant stiripentol acts directly on the GABAA receptor as a positive allosteric modulatorNeuropharmacology, 2009
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008
- IN VITRO AND IN VIVO INHIBITORY EFFECT OF STIRIPENTOL ON CLOBAZAM METABOLISMDrug Metabolism and Disposition, 2006